Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide

Palladini, Giovanni; Russo, Paola; Foli, Andrea; Milani, Paolo; Lavatelli, Francesca; Obici, Laura; Nuvolone, Mario; Brugnatelli, Silvia; Invernizzi, Rosangela; Merlini, Giampaolo
January 2012
Annals of Hematology;Jan2012, Vol. 91 Issue 1, p89
Academic Journal
The increasing number of effective agents allows rescue therapy of patients with light-chain (AL) amyloidosis refractory to ≥2 previous treatments. Lenalidomide is effective in this disease and its toxicity profile encourages its use in salvage regimens. All the patients with AL amyloidosis refractory to both melphalan and bortezomib referred to our center between July 2007 and July 2009 were treated with the combination of lenalidomide and dexamethasone. Twenty-four consecutive patients were enrolled. Seventy-nine percent were also refractory to thalidomide. Two patients died before evaluation of response, and 50% experienced severe adverse events. Survival was significantly shorter in subjects with troponin I >0.1 ng/mL and in patients diagnosed <18 months before treatment initiation. Hematologic response was observed in 41% of patients and prolonged survival (median 10 months vs. not reached, P = 0.005) independently from troponin I concentration and from pre-treatment disease duration. Salvage therapy beyond second line of treatment can improve survival in AL amyloidosis and lenalidomide plus dexamethasone is a valuable option in this setting.


Related Articles

  • Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study. Yeo-Kyeoung Kim; Sang-Kyun Sohn; Jae-Hoon Lee; Deok-Hwan Yang; Joon-Ho Moon; Jae-Sook Ahn; Hyeoung-Joon Kim; Je-Jung Lee // Annals of Hematology;May2010, Vol. 89 Issue 5, p475 

    The clinical efficacy and safety of a four-drug combination of bortezomib, cyclophosphamide, thalidomide, and dexamethasone was assessed for patients with relapsed or refractory multiple myeloma. Seventy patients received at least two cycles of treatment with bortezomib 1.3 mg/m2 intravenously...

  • Dijagnostika i lečenje primarne amiloidoze. Djunić, Irena; Tomin, Dragica; Peruničić, Maja; Vidović, Ana; Čemerikić, Vesna; Djurašinović, Vladislava; Jaković, Ljubomir; Janković, Gradimir // Vojnosanitetski Pregled: Military Medical & Pharmaceutical Journ;Sep2010, Vol. 67 Issue 9, p781 

    Backgraund. Primary amyloidosis belongs to a group of monoclonal plasma cell disorders, characterized by extracellular deposition of immunoglobulin light chain fibrils in various tissues and subsequent multiorgan dysfunction. Case report. We present a 51-year-old female with 2-years history of...

  • Successful management of refractory pleural effusion due to systemic immunoglobulin light chain amyloidosis by vincristine adriamycin dexamethasone chemotherapy: a case report. Araoka, Toshikazu; Takeoka, Hiroya; Nishioka, Keisuke; Ikeda, Masaki; Kondo, Makiko; Hoshina, Azusa; Kishi, Seiji; Araki, Makoto; Mimura, Rokuro; Murakami, Taichi; Mima, Akira; Nagai, Kojiro; Abe, Hideharu; Doi, Toshio // Journal of Medical Case Reports;2010, Vol. 4 Issue 1, p1 

    Introduction: Refractory pleural effusion in systemic immunoglobulin light chain amyloidosis without cardiac decompensation is rarely reported and has a poor prognosis in general (a median survival of 1.6 months). Moreover, the optimum treatment for this condition is still undecided. This is the...

  • Primary Amyloidosis. Barth, Werner F.; Glenner, George G.; Waldmann, Thomas A.; Zellis, Robert F. // Annals of Internal Medicine;Oct68, Vol. 69 Issue 4, p786 

    Presents the text of a combined clinical staff conference at the Clinical Center, Bethesda, Maryland, about primary amyloidosis. Presentation of papers; Keynote speakers; Observations on the relationship between immunoglobulins and amyloid.

  • Towards an understanding of amyloidogenesis. Kelly, Jeffrey W. // Nature Structural Biology;May2002, Vol. 9 Issue 5, p323 

    Provides insight into the structural continuum associated with the process of amyloidosis. Reason amyloid diseases are referred to as misfolding diseases; Evaluation on the structural features of the amyloid-competent intermediate formed at pH 3.6; Fibril structural elements.

  • Renal involvement in systemic amyloidosis--an Italian retrospective study on epidemiological and clinical data at diagnosis. Franco Bergesio; Anna Maria Ciciani; Marisa Santostefano; Rachele Brugnano; Marco Manganaro; Giovanni Palladini; Anna Maria Di Palma; Marco Gallo; Pier Luigi Tosi; Maurizio Salvadori; on behalf of the Immunopathology Group of the Italian Society of Nephrology // Nephrology Dialysis Transplantation;May2007, Vol. 22 Issue 6, p1608 

    Background. Few data are available on epidemiology and clinical picture of renal involvement in different forms of systemic amyloidosis. Methods. Patients with biopsy-proven systemic amyloidosis diagnosed in Italy between January 1995 and December 2000 were selected from 49 Nephrology and...

  • Chronic renal failure secondary to systemic amyloidosis associated with gastrointestinal stromal tumour. Muñiz-Pacios, Laura; Morales-Ruiz, Enrique; Aguilar, Fernando; García-Martín, Florencio // Nefrologia;2013, Vol. 33 Issue 4, p620 

    A letter to the editor is presented in response to the article "Chronic renal failure secondary to systemic amyloidosis associated with gastrointestinal stromal tumour," that was published in a previous issue.

  • Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide. Lau, I-Jun; Smith, Dean; Aitchison, Robin; Blesing, Norbert; Roberts, Pamela; Peniket, Andrew; Yong, Kwee; Rabin, Neil; Ramasamy, Karthik // Annals of Hematology;Apr2015, Vol. 94 Issue 4, p643 

    Treatment options are limited in myeloma relapsed or refractory to both bortezomib and lenalidomide (double-relapsed/refractory multiple myeloma; DRMM). Bendamustine is an antitumour agent that has efficacy in relapsed myeloma. We retrospectively analysed data from 30 DRMM patients who received...

  • Manually respiratory-triggered single-shot fast spin-echo: a non-breath-hold T[sub 2]-weighted method for liver lesion detection. O'Riordan, E.; Haider, M.A.; O'Malley, M.E.; Khalili, K.; Ibach, K.; Lockwood, G.A.; Bahadorani, B. // Canadian Association of Radiologists Journal;Dec2003, Vol. 54 Issue 5, p289 

    Objectives: To determine whether manual respiratory triggering of a T[sub 2]-weighted single-shot fast spin-echo sequence (M-SSFSE) improves detection and characterization of liver lesions compared with conventional breath-held single-shot fast spin-echo (C-SSFSE) technique. Methods: M-SSFSE is...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics